Gossamer Bio Inc. (NASDAQ: GOSS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT GOSSAMER BIO INC.

Gossamer Bio Inc. (NASDAQ: GOSS)
Listen to this Section


$0.17
-0.0098 ( -5.51% ) 7.1M

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Clinical Trial Pipeline Stages


Drug Name Stage
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor)DetailsLung disease, Pulmonary hypertension associated with interstitial lung disease Phase 3
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor)DetailsPulmonary arterial hypertension, Lung disease, Rare diseases Phase 2
GB1275 (Oral CD11b modulator)DetailsSolid tumor/s, Esophageal cancer, Cancer, Gastric cancer Failed
GB001 (Oral DP2 Antagonist)DetailsAsthma Failed

Market Data


Open $0.17
Previous Close $0.18
Volume 7.1M
Market Cap $44.19M
Day Range $0.17 - $0.18
52 Week Range $0.16 - $3.87
Shares Outstanding 234.70M
Change % -5.51%
Net Change ▼ -0.0098
Insider Ownership -0.05%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2019
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -6,039,876.00

Date Type Amount Purchased Purchaser
2024-03-28 Sale -6430.00 Giraudo Bryan
2024-03-28 Sale -23172.00 Hasnain Faheem
2024-03-28 Sale -6430.00 Christian Waage
2024-03-19 Sale -4018.00 Peterson Caryn
2024-03-19 Sale -4018.00 Aranda Richard
2024-03-12 Sale -230000.00 Nathan Steven D
2024-03-12 Sale -230000.00 Drynan Skye
2024-01-04 Sale -375000.00 Christian Waage
2024-01-04 Sale -375000.00 Peterson Caryn
2024-01-04 Sale -487500.00 Aranda Richard

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 76 Nov 05, 2025
8-k 8K-related 14 Nov 05, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
8-k 8K-related 12 Sep 25, 2025
4 Insider transactions 1 Aug 20, 2025

Latest News


× Before browsing our site, please accept our cookies policy